← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Glycomantra, Inc.
Halethorpe, MD
$5,733,179
Total funding
7
Grants
Funding over time
peak $2.1M · FY2016–24$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,733,179 · 7
By mechanism
R44$3,674,654 · 1
R43$1,760,008 · 5
R41$298,517 · 1
Investigators at Glycomantra, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes$1,864,171
R44 · FY2024 · DK
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes$1,810,483
R44 · FY2023 · DK
Targeting galectin-3 to overcome insulin resistance in type 2 diabetes$300,000
R43 · FY2020 · DK
Targeting galectin-3 to intervene COVID-19$300,000
R43 · FY2022 · AI
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy$300,000
R43 · FY2018 · CA
GRIM19 for head and neck cancer therapy$298,517
R41 · FY2017 · CA
Targeting galectin-3 for treatment of NASH mediated fibrosis$298,490
R43 · FY2018 · DK
Targeting galectin-3 to intervene COVID-19$296,637
R43 · FY2023 · AI
Targeting galectin-3 for prostate cancer therapy$224,881
R43 · FY2016 · CA
Targeting galectin-3 for prostate cancer therapy$40,000
R43 · FY2016 · CA